Drugs / M254
last change Jun 2021 re-read 2 minutes ago

M254

Developed for
autoimmune thrombocytopenic purpura
Investigated by
Momenta Pharmaceuticals, Inc.

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03866577 Dec 2018 → Jun 2021 autoimmune thrombocytopenic purpura Momenta Pharmaceuticals, Inc. Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as M254 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03866577
Route Intravenous “M254 administered as intravenous infusion” NCT03866577